Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa study of fentanyl aerosol for breakthrough cancer pain in China
CTR20221762Phase 2Active
- Sponsor
- Beijing Kenuo Pharmaceutical Technology
- Start
- Oct 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fentanyl in breakthrough cancer pain (BTcP), sponsored by Beijing Kenuo Pharmaceutical Technology. Started Oct 2022; status: active.
02
Drugs
fentanyl
03
Conditions
breakthrough cancer pain (BTcP)
Beyond the preview
Go deeper on CTR20221762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221762.